

REMARKS

Upon entry of the present amendments, claims 52-65, 67, and 71-76 are pending in the application. Claims 68-70 have been cancelled herein, without prejudice or disclaimer. New claim 76 has been added herein. Support for this claim is found at least at page 2, lines 19-25 and page 6, lines 16-22. Thus, no new matter has been added

Applicants acknowledge with appreciation that the rejection of claims 66-67 and 71-72 under 35 U.S.C. § 112, first paragraph for lack of enablement; the rejection of claims 61-62 under 35 U.S.C. § 112, second paragraph for lack of proper antecedent basis; the rejection of claim 72 under 35 U.S.C. § 112, second paragraph as being indefinite; and the rejection of claims 73-75 under 35 U.S.C. § 112, second paragraph as being indefinite have been withdrawn.

Applicants also note with appreciation that the Examiner has indicated that claims 52-65, 67, and 71-75 have been allowed. (*See Office Action Summary*).

Claim Rejections -- 35 U.S.C. § 112, first paragraph

Claims 68-70 have been rejected under 35 U.S.C. § 112, first paragraph, "because the specification, while being enabling for a method for producing a population of highly enriched human CNS stem cells using publicly available and identifiable/deposited antibodies, does not reasonably provide enablement for methods of isolating highly enriched populations of human CNS stem cells from adult brain or spinal cord areas or from undefined generic neural stem cell cultures where no neural stem cells exist." (*Office Action at page 3*).

Applicants have herein cancelled claims 68-70, without prejudice or disclaimer. Thus, this rejection is moot and should be withdrawn.


Moreover, Applicants contend that this rejection does not apply to new claim 76. Specifically, new claim 76 depends from any one of claims 52, 57, 58, 59, 71, or 73, each of which have been allowed by the Examiner. Accordingly, Applicants submit that new claim 76 is fully enabled by the as-filed specification and should be allowed.

CONCLUSION

Applicants submit that this paper is fully responsive and that the application is in condition for allowance. Such action is respectfully requested. Should any questions or issues arise concerning the application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

No additional fees are believed due in connection with this paper. However, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Reference 17810-510 NATL (SCI-10 NATL).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ivor R. Elrifi", is written over a horizontal line. The signature is fluid and cursive.

Ivor R. Elrifi, Reg. No. 39,529

Christina K. Stock, Reg. No. 45,899

Attorneys for Applicant

Telephone: (617) 542-6000

Facsimile: (617) 542-2241

Customer Number **30623**

Date: October 11, 2005